Search for a command to run...
No recent news available for this stock.
Conference call summary is not available for this stock.
Jenburkt Pharmaceuticals Ltd. is currently undervalued with a low PE ratio and zero debt, but faces challenges in growth and profitability. Among its peers, it stands out as a potential value pick, despite having no growth metrics to show. Companies like Sun Pharmaceutical and Mankind Pharma exhibit strong profitability but are relatively overvalued, indicating an opportunity for investors to consider Jenburkt as a contrarian play.
Highest revenue growth YoY at 8.42% and strong profitability metrics.
Strongest revenue growth of 18.12% YoY and high ROE of 23.15%.
High ROE at 21.76% and solid growth with 16.54% revenue increase YoY.